[{"id":"743f2392-3b37-49eb-aa59-6285b6c06740","acronym":"","url":"https://clinicaltrials.gov/study/NCT00121225","created_at":"2021-01-18T00:24:32.398Z","updated_at":"2024-07-02T16:37:03.407Z","phase":"Phase 2","brief_title":"Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma","source_id_and_acronym":"NCT00121225","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TFF1","pipe":"","alterations":" ","tags":["TFF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 09/01/2005","start_date":" 09/01/2005","primary_txt":" Primary completion: 03/01/2009","primary_completion_date":" 03/01/2009","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2019-01-29"},{"id":"0f561753-b711-46ab-84d1-9c3e2b2faf2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00290758","created_at":"2021-01-18T00:59:31.316Z","updated_at":"2024-07-02T16:37:25.868Z","phase":"Phase 2b","brief_title":"Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer","source_id_and_acronym":"NCT00290758","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • TFF1","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA • TFF1"],"overall_status":"Completed","enrollment":" Enrollment 126","initiation":"Initiation: 01/01/2006","start_date":" 01/01/2006","primary_txt":" Primary completion: 03/01/2009","primary_completion_date":" 03/01/2009","study_txt":" Completion: 07/01/2009","study_completion_date":" 07/01/2009","last_update_posted":"2017-02-08"},{"id":"3d38fdc0-92a6-41ab-9768-ebd18f75b59e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00073073","created_at":"2021-01-18T00:11:27.292Z","updated_at":"2024-07-02T16:37:32.131Z","phase":"Phase 2","brief_title":"Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer","source_id_and_acronym":"NCT00073073","lead_sponsor":"Georgetown University","biomarkers":" BRCA1 • BRCA2 • PCNA • TFF1 • LEP","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PCNA expression","tags":["BRCA1 • BRCA2 • PCNA • TFF1 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PCNA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 11/01/2003","start_date":" 11/01/2003","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2016-05-17"}]